These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 26701087)

  • 21. Nursing perspectives on trastuzumab emtansine for the treatment of metastatic breast cancer.
    Bourdeanu L; Luu T
    Clin J Oncol Nurs; 2013 Oct; 17(5):E58-62. PubMed ID: 24080060
    [TBL] [Abstract][Full Text] [Related]  

  • 22. T-DM1 as a New Treatment Option for Patients with Metastatic HER2-positive Breast Cancer in Clinical Practice.
    Michel LL; Bermejo JL; Gondos A; Marmé F; Schneeweiss A
    Anticancer Res; 2015 Sep; 35(9):5085-90. PubMed ID: 26254411
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trastuzumab emtansine in locally advanced or metastatic HER2 positive breast cancer; GENESIS-SEFH drug evaluation report.
    Miranda Romero P; Marín Gil R
    Farm Hosp; 2015 May; 39(3):171-5. PubMed ID: 26005893
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Response of symptomatic brain metastases from HER-2 overexpressing breast cancer with T-DM1.
    de Vries CL; Linn SC; Brandsma D
    J Neurooncol; 2016 Apr; 127(2):401-3. PubMed ID: 26732082
    [No Abstract]   [Full Text] [Related]  

  • 25. Targeting HER2 with T-DM1, an Antibody Cytotoxic Drug Conjugate, is Effective in HER2 Over Expressing Bladder Cancer.
    Hayashi T; Seiler R; Oo HZ; Jäger W; Moskalev I; Awrey S; Dejima T; Todenhöfer T; Li N; Fazli L; Matsubara A; Black PC
    J Urol; 2015 Oct; 194(4):1120-31. PubMed ID: 26047983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.
    Krop IE; Beeram M; Modi S; Jones SF; Holden SN; Yu W; Girish S; Tibbitts J; Yi JH; Sliwkowski MX; Jacobson F; Lutzker SG; Burris HA
    J Clin Oncol; 2010 Jun; 28(16):2698-704. PubMed ID: 20421541
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: a case series.
    Sibaud V; Niec RE; Schindler K; Busam KJ; Roché H; Modi S; Delord JP; Lacouture ME
    Breast Cancer Res Treat; 2014 Jul; 146(2):451-6. PubMed ID: 24929675
    [TBL] [Abstract][Full Text] [Related]  

  • 28. T-DM1 aids patients with advanced breast cancer.
    Cancer Discov; 2013 Dec; 3(12):OF5. PubMed ID: 24327714
    [No Abstract]   [Full Text] [Related]  

  • 29. Trastuzumab-deBouganin Conjugate Overcomes Multiple Mechanisms of T-DM1 Drug Resistance.
    Dillon RL; Chooniedass S; Premsukh A; Adams GP; Entwistle J; MacDonald GC; Cizeau J
    J Immunother; 2016 Apr; 39(3):117-26. PubMed ID: 26938945
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging strategies for the dual inhibition of HER2-positive breast cancer.
    Konecny GE
    Curr Opin Obstet Gynecol; 2013 Feb; 25(1):55-65. PubMed ID: 23241641
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Breast cancer brain metastases responding to primary systemic therapy with T-DM1.
    Bartsch R; Berghoff AS; Preusser M
    J Neurooncol; 2014 Jan; 116(1):205-6. PubMed ID: 24065570
    [No Abstract]   [Full Text] [Related]  

  • 32. HER2-positive breast cancer: a new piece of the puzzle.
    Gnant M; Bartsch R; Steger GG
    Lancet Oncol; 2014 Jun; 15(7):668-9. PubMed ID: 24793817
    [No Abstract]   [Full Text] [Related]  

  • 33. Interest in "smart bombs" explodes.
    Cancer Discov; 2012 Oct; 2(10):864. PubMed ID: 23071018
    [No Abstract]   [Full Text] [Related]  

  • 34. The promise of antibody-drug conjugates.
    Teicher BA; Doroshow JH
    N Engl J Med; 2012 Nov; 367(19):1847-8. PubMed ID: 23134386
    [No Abstract]   [Full Text] [Related]  

  • 35. Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic breast cancer.
    Niculescu-Duvaz I
    Curr Opin Mol Ther; 2010 Jun; 12(3):350-60. PubMed ID: 20521224
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer.
    Bender BC; Schaedeli-Stark F; Koch R; Joshi A; Chu YW; Rugo H; Krop IE; Girish S; Friberg LE; Gupta M
    Cancer Chemother Pharmacol; 2012 Oct; 70(4):591-601. PubMed ID: 22886072
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer.
    Junutula JR; Flagella KM; Graham RA; Parsons KL; Ha E; Raab H; Bhakta S; Nguyen T; Dugger DL; Li G; Mai E; Lewis Phillips GD; Hiraragi H; Fuji RN; Tibbitts J; Vandlen R; Spencer SD; Scheller RH; Polakis P; Sliwkowski MX
    Clin Cancer Res; 2010 Oct; 16(19):4769-78. PubMed ID: 20805300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer: a review.
    Mathew J; Perez EA
    Curr Opin Oncol; 2011 Nov; 23(6):594-600. PubMed ID: 21986845
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HER2 expression and efficacy of T-DM1.
    Montemurro F
    Breast Cancer Res; 2014 Dec; 16(6):478. PubMed ID: 25472666
    [No Abstract]   [Full Text] [Related]  

  • 40. Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling.
    Montero JC; García-Alonso S; Ocaña A; Pandiella A
    Oncotarget; 2015 Oct; 6(30):30057-71. PubMed ID: 26336133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.